Not finding it? Sign in to also search OpenAlex live.
-
212 Multiplex qPCR hotspot testing of pathogenic POLE mutations: a rapid, simple and reliable approach for POLE assessment in endometrial cancer2021 International Journal of Gynecological Cancer article Medicine Endometrial and Cervical Cancer Treatments Open access
AS Van den Heerik, Natalja T. ter Haar, Nanda Horeweg, Tom van Wezel, Carien L. Creutzberg, Vincent T.H.B.M. Smit, +1 more
4citations -
CCTG EN10: A phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (EC)—RAINBO BLUE and TAPER.2023 Journal of Clinical Oncology conference-abstract Medicine Endometrial and Cervical Cancer Treatments Open access
Jessica Nell McAlpine, Kathy Chai-Zung Han, Mary A. Kinloch, Maroie Barkati, Sarah Elizabeth Ferguson, Anthony Fyles, +13 more
8citations -
Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma2024 Cancer Immunology Immunotherapy article Medicine Cancer Immunotherapy and Biomarkers Open access
Judith M. Versluis, Esmée P. Hoefsmit, H. Shehwana, P. Dimitriadis, J. Sanders, A. Broeks, +1 more
6citations -
Molecular Classification Outperforms Histologic Classification in Prognostication of High-grade Endometrial Carcinomas With Undifferentiated and Sarcomatous Components2024 The American Journal of Surgical Pathology article Medicine Endometrial and Cervical Cancer Treatments Open access
Phoebe M. Hammer, Aihui Wang, Lisa Vermij, Sabrina Zdravkovic, Lucas Miecho Heilbroner, Emily Elizabeth Ryan, +9 more
14citations -
406 Prognostic relevance of the molecular endometrial cancer classification among patients staged by lymphadenectomy and/or without adjuvant treatment2021 Endometrial cancer conference-paper Medicine Endometrial and Cervical Cancer Treatments Open access
Alicia León‐Castillo, Nanda Horeweg, Elke E.M. Peters, Tessa A. Rutten, Natalja T. ter Haar, Vincent T.H.B.M. Smit, +7 more
1citations -
Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer2023 Journal of Clinical Oncology article Medicine Endometrial and Cervical Cancer Treatments Open access
Nanda Horeweg, Remi A. Nout, Ina Maria Jurgenliemk-Schulz, Ludy C.H.W. Lutgens, Jan J. Jobsen, Marie A.D. Haverkort, +38 more
104citations -
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
Anne Sophie V M van den Heerik, Nanda Horeweg, Marie A.D. Haverkort, Nienke Kuijsters, S Kommoss, Friederike L.A. Koppe, +24 more
66citations -
482 Tertiary lymphoid structures as markers of anti-tumor immunity with independent prognostic value in the PORTEC-3 trial of high-risk endometrial cancer2021 International Journal of Gynecological Cancer article Medicine Endometrial and Cervical Cancer Treatments Open access
Nanda Horeweg, Hagma H. Workel, Dominik Loiero, David N. Church, Lisa Vermij, Alicia León‐Castillo, +13 more
0citations -
Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts
Sarah Volinsky-Fremond, Sonali Andani, Jurriaan Barkey Wolf, Jouke Dijkstra, Sinead Melsbach, Jan J. Jobsen, +18 more
134citations -
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy2020 Journal of Clinical Oncology article Medicine Endometrial and Cervical Cancer Treatments Open access cited by 1 patent
Alicia León‐Castillo, Stephanie M. de Boer, Melanie E. B. Powell, Linda Mileshkin, Helen J MacKay, Alexandra F. Leary, +16 more
877citations